AVITA Medical (RCEL) Q3 2024 earnings summary

Executive summary

• Commercial revenue reached as high as $23.3 million in Q3 2024, up 65% year-over-year, driven by RECELL GO adoption, new account penetration, and portfolio expansion.

• Over 75% of revenue transitioned to RECELL GO within four months of FDA approval, demonstrating strong execution and operational agility.

• Expanded account base to approximately 300, with a focus on converting nearly 60 accounts in the Value Analysis Committee process in Q4.

• Strategic priorities include new product launches (Cohealyx, RECELL GO Mini), expanded indications, and international growth in Europe and Australia in 2025.

• Exclusive agreements for Cohealyx and PermeaDerm support portfolio expansion and future growth.

Financial highlights

• Q3 2024 commercial revenue reported between $19.5 million and $23.3 million, up 43%–65% year-over-year.

• Gross profit margin was 83.7% for Q3 2024, slightly down from 84.5% in Q3 2023.

• Operating expenses rose to $30.2 million from $21.1 million, mainly due to increased sales, marketing, and G&A costs.

• Net loss for Q3 2024 was $16.2 million ($0.62 per share), compared to $8.7 million ($0.34 per share) in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $44.4 million as of September 30, 2024.

Outlook and guidance

• Q4 2024 commercial revenue expected between $22.3 million and $24.3 million, representing 58%–72% year-over-year growth.

• Full-year 2024 revenue guidance maintained at $68 million to $70 million.

• Path to cash flow breakeven and GAAP profitability targeted for Q3 2025, with minimal headcount growth.

• RECELL GO Mini and Cohealyx launches expected in early 2025, pending FDA clearance.

• Sufficient cash reserves projected to fund operations for the next 12 months.